Actively Recruiting

Age: 18Years +
All Genders
NCT06599619

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Led by John Kirkwood · Updated on 2026-01-26

30

Participants Needed

1

Research Sites

218 weeks

Total Duration

On this page

Sponsors

J

John Kirkwood

Lead Sponsor

M

Melanoma Research Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.

CONDITIONS

Official Title

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have at least two atypical nevi of 4 mm diameter or larger
  • Have a documented history of melanoma
  • Are 18 years of age or older
  • If female and of childbearing potential, agree to use effective contraception if sexually active
  • Are candidates for adjuvant single-agent anti-PD1 therapy
  • Provide written informed consent before joining the study
Not Eligible

You will not qualify if you...

  • Have non-malignant diseases or conditions that prevent anti-PD1 therapy, such as significant immune suppression or active autoimmune disease requiring immunosuppressive treatment
  • Have previously received anti-PD1 therapy
  • Have a history of other active, non-melanoma cancers
  • Are currently receiving other anti-cancer treatments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

Loading map...

Research Team

D

Danielle L Bednarz, RN

CONTACT

A

Amy Rose, RN

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here